In short
KB707 is an investigational therapy being studied for the treatment of solid tumors. It is a modified herpes simplex virus type 1 designed to deliver interleukin-12 and an antibody against programmed cell death protein 1 directly to tumors. One clinical trial is currently authorised in the European Union, a Phase 1 study planning to enroll 90 participants to evaluate the safety of inhaled KB707 alone and in combination with other cancer treatments.
Key points
- KB707 is an investigational therapy for solid tumors, not yet an authorised medicine.
- One Phase 1 trial is authorised, with a planned enrollment of 90 participants.
- The trial studies inhaled KB707 alone and in combination with docetaxel or immune checkpoint inhibitors.
- The main goal is to measure the safety and tolerability of the treatment.
- The trial is currently authorised but not yet recruiting.
- KB707 is a modified herpes simplex virus that carries genes for interleukin-12 and an anti-PD-1 antibody.
What is KB707?
KB707 is an investigational substance, meaning it is not yet approved as a medicine. Its full name is herpes simplex virus 1 encoding interleukin-12 and an antibody against programmed cell death protein 1. The short label used in the trial records is KB707. It belongs to a group of experimental cancer treatments called oncolytic viruses, which are viruses modified to infect and attack cancer cells.
The trial record describes KB707 as a drug given by inhalation use, in combination with docetaxel, a chemotherapy medicine given by intravenous infusion.
How does KB707 work?
KB707 is based on herpes simplex virus type 1, which has been genetically modified to carry two additional therapeutic genes. One gene encodes interleukin-12, a protein that stimulates the immune system. The other encodes an antibody against programmed cell death protein 1 (PD-1), a checkpoint protein that can prevent immune cells from attacking cancer. By delivering these two agents directly to tumors, KB707 is intended to help the immune system recognise and fight cancer cells.
The exact mechanism is still being investigated in clinical trials. The current Phase 1 study is designed to evaluate safety and tolerability first, before any conclusions about effectiveness can be drawn.
Which conditions is KB707 studied for?
The authorised clinical trial lists one condition:
- Solid tumor — a general term for cancers that form a mass in organs or tissues, such as lung, breast, or colon cancer, as opposed to blood cancers.
The trial does not specify particular cancer types, so it appears open to patients with various solid tumors.
How is KB707 given?
In the authorised trial, KB707 is given by inhalation use, meaning it is breathed into the lungs. The trial also includes docetaxel, which is given by intravenous infusion, meaning it is delivered directly into a vein.
No other pharmaceutical forms or routes of administration are listed in the trial record.
What do the clinical trials show?
One clinical trial of KB707 is currently authorised in the European Union. The trial is a Phase 1 study, which is the earliest stage of testing in humans, focused mainly on safety. It plans to enroll 90 participants.
The trial has two parts: it evaluates KB707 as a monotherapy and in combination with other treatments, including immune checkpoint inhibitors with or without chemotherapy, and with docetaxel. The primary outcome is the frequency, severity, and relatedness of adverse events and serious adverse events, which means the main goal is to find out how safe and tolerable the treatment is.
The trial status is authorised, meaning it has received regulatory approval to proceed but is not yet recruiting participants.
What side effects are known?
No side effects of KB707 are described in the available trial record. Since the trial is still in Phase 1 and not yet recruiting, no safety data from human participants are available. The primary purpose of the authorised study is precisely to collect information on adverse events and serious adverse events.